Botulinum Toxin Type A Injections May Improve Gait Kinematics Towards Typically Developing Values in Children with Cerebral Palsy: A Preliminary Report
Presenter Type
UNO Graduate Student (Doctoral)
Major/Field of Study
Biomechanics
Author ORCID Identifier
0000-0003-2500-9557
Advisor Information
David Kingston, PhD
Location
CEC RM #201/205/209
Presentation Type
Poster
Poster Size
40 x 40
Start Date
22-3-2024 10:30 AM
End Date
22-3-2024 11:45 AM
Abstract
Children with cerebral palsy (CP) typically present with muscle spasticity that impairs walking. A common treatment to reduce muscle spasticity is botulinum toxin type A (BoNT-A) injections. The effectiveness of lower-limb BoNT-A injections is typically performed with physical therapy assessments, however, they do not tell us how their walking is impacted following BoNT-A. Therefore, the purpose of this study was to quantify changes in walking from baseline to 6-weeks after lower-extremity BoNT-A injection. Three children with spastic CP (age: 11.3 ± 7.0 years, height: 1.41 ± 2.7 m, weight: 55.1 ± 26.9 kg) who received lower-limb BoNT-A completed barefoot walking trials before BoNT-A injection and 6-weeks after to assess changes in their walking via root mean square (ΔRMS). Notable differences were observed in the sagittal (side profile) and transverse (top-down) planes of the ankle (Sagittal | T02: ∆RMSMA = 10.02°; T03: ∆RMSMA = -7.05°; Transverse | T03: ∆RMSMA = -28.11°; T07: ∆RMSLA = 9.36°), knee (Sagittal | T03: ∆RMSMA = -16.34°; Transverse | T07: ∆RMSMA = -8.58°, ∆RMSLA = 5.67°), and hip (Sagittal | T02: ∆RMSMA = 15.14°, ∆RMSLA = 5.64°; T03: ∆RMSMA = -19.29°; T07: ∆RMSLA = -7.87°; Transverse | T03: ∆RMSMA = 8.37°; T07: ∆RMSLA = 6.49°). Preliminary results suggest that BoNT-A injections could improve joint movement in children with CP towards typically developing values. To provide insight on BoNT-A’s short-term effectiveness on improving joint movement during walking, additional 3-month follow-up data are needed.
Botulinum Toxin Type A Injections May Improve Gait Kinematics Towards Typically Developing Values in Children with Cerebral Palsy: A Preliminary Report
CEC RM #201/205/209
Children with cerebral palsy (CP) typically present with muscle spasticity that impairs walking. A common treatment to reduce muscle spasticity is botulinum toxin type A (BoNT-A) injections. The effectiveness of lower-limb BoNT-A injections is typically performed with physical therapy assessments, however, they do not tell us how their walking is impacted following BoNT-A. Therefore, the purpose of this study was to quantify changes in walking from baseline to 6-weeks after lower-extremity BoNT-A injection. Three children with spastic CP (age: 11.3 ± 7.0 years, height: 1.41 ± 2.7 m, weight: 55.1 ± 26.9 kg) who received lower-limb BoNT-A completed barefoot walking trials before BoNT-A injection and 6-weeks after to assess changes in their walking via root mean square (ΔRMS). Notable differences were observed in the sagittal (side profile) and transverse (top-down) planes of the ankle (Sagittal | T02: ∆RMSMA = 10.02°; T03: ∆RMSMA = -7.05°; Transverse | T03: ∆RMSMA = -28.11°; T07: ∆RMSLA = 9.36°), knee (Sagittal | T03: ∆RMSMA = -16.34°; Transverse | T07: ∆RMSMA = -8.58°, ∆RMSLA = 5.67°), and hip (Sagittal | T02: ∆RMSMA = 15.14°, ∆RMSLA = 5.64°; T03: ∆RMSMA = -19.29°; T07: ∆RMSLA = -7.87°; Transverse | T03: ∆RMSMA = 8.37°; T07: ∆RMSLA = 6.49°). Preliminary results suggest that BoNT-A injections could improve joint movement in children with CP towards typically developing values. To provide insight on BoNT-A’s short-term effectiveness on improving joint movement during walking, additional 3-month follow-up data are needed.